Patents by Inventor Clive Svendsen

Clive Svendsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970714
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 30, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11952592
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 9, 2024
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11877896
    Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: January 23, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Pablo Avalos, Doniel Drazin, Clive Svendsen
  • Publication number: 20240009325
    Abstract: The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by introducing normal human MCT8 into the subject's cells in order to increase T3 in the subject's brain.
    Type: Application
    Filed: July 11, 2023
    Publication date: January 11, 2024
    Inventors: Samuel REFETOFF, Roy WEISS, Khemraj HIRANI, Clive SVENDSEN, Pablo AVALOS, Gad VATINE
  • Publication number: 20230340420
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 26, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20230333092
    Abstract: Described herein are the effects of continuous media perfusion on SC-Chips and the observed activation of pronounced neural tissue growth and vascular recruitment into the neural tissue channel. ALS patient chip overexpression of known neurodegenerative disease biomarkers neurogranin and neurofilament family members are also described and utilized for the invention.
    Type: Application
    Filed: September 22, 2021
    Publication date: October 19, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Samuel Sances, Clive Svendsen
  • Publication number: 20230174946
    Abstract: Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.
    Type: Application
    Filed: April 30, 2021
    Publication date: June 8, 2023
    Applicants: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Barry R. Stripp, Apoorva Mulay, Bindu Konda, Arun Sharma, Clive Svendsen, Vaithilingaraja Arumugaswami, Dhruv Sareen, Hanan Shaharuddin, Victoria Wang, Roberta S. Santos
  • Publication number: 20230159896
    Abstract: Described herein is a human, cardiovascular platform for assessing cardiotoxicity of novel/existing chemotherapeutic agents that takes advantage of microfluidic organ chip systems to examine interaction between hiPSC-derived cardiovascular cells in an integrated system. Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and human induced pluripotent stem cell derived endothelial cells (hiPSC-ECs) can serve as an in-vitro platform for assessing disease pathology, including infectious disease, evaluate drug efficacy, toxicity, cardiotoxicity and cardioprotection. This includes evaluating VEGFR2/PDGFR-inhibiting tyrosine kinase inhibitors and drug efficacy in a viral infection model, including coronaviruses. They are scalable, functionally-active cell types that mimic the cells comprising the myocardium and systemic vasculature.
    Type: Application
    Filed: April 30, 2021
    Publication date: May 25, 2023
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Arun Sharma, Samuel Sances, Clive Svendsen
  • Patent number: 11572545
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 7, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 11473061
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 18, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani
  • Publication number: 20220282221
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: February 23, 2022
    Publication date: September 8, 2022
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11359242
    Abstract: Modeling Amyotrophic Lateral Sclerosis (ALS) with human induced pluripotent stem cells (iPSCs) aims to reenact embryogenesis, maturation, and aging of spinal motor neurons (spMNs) in vitro. As the maturity of spMNs grown in vitro compared to spMNs in vivo remains largely unaddressed, it is unclear to what extent this in vitro system captures critical aspects of spMN development and molecular signatures associated with ALS. Here, the Inventors compared transcriptomes among iPSC-derived spMNs, fetal, and adult spinal tissues. The Inventors resolved gene networks and pathways associated with spMN maturation and aging. These networks enriched for familial ALS genetic variants and were affected in sporadic ALS. Altogether, the Inventors' findings suggest that developing strategies to further mature and age iPSC-derived spMNs will provide more effective iPSC models of ALS.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 14, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Ritchie Ho, Clive Svendsen
  • Patent number: 11326149
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 10, 2022
    Assignee: EMULATE, INC.
    Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
  • Patent number: 11253645
    Abstract: The present invention teaches apparatuses, systems and methods for performing a variety of medical procedures, including those involving introducing one or more substances into a subject's body. In some embodiments, the invention teaches automatically performing guided injections into a tissue site (e.g. spinal cord) of a subject by using one or more electronically operated components including a cannula, a syringe pump, and a stereotactic device.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 22, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Pablo Avalos, Doniel Drazin, Clive Svendsen, Michael John Baker, Mark Sasha Drlik
  • Patent number: 11174462
    Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: November 16, 2021
    Assignees: EMULATE, Inc., Cedars-Sinai Medical Center
    Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sanees, Clive Svendsen, Daniel Levner, Dhruv Sareen
  • Publication number: 20210024955
    Abstract: Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to Parkinsonian patients and is currently being tested in a Phase 1/2a clinical trial for ALS patients. However, chronic trophic factor delivery prohibits dose adjustment or shut off in the event of side effects. To address this, the Inventors engineered a stably integrating, third-generation doxycycline-regulated vector, allowing inducible and reversible expression of a therapeutic molecule Human iPSC-derived neural progenitors were stably transfected with the vector, expanded and transplanted into the adult mouse brain. The Inventors observed that the addition and withdrawal of doxycycline led to GDNF expression that could be induced and reversed multiple times, demonstrating that doxycycline can penetrate the graft and regulate transgene expression in vivo.
    Type: Application
    Filed: March 15, 2019
    Publication date: January 28, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Clive Svendsen, Joshua Breunig, Aslam Akhtar
  • Publication number: 20210000880
    Abstract: Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic ?-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D ?-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Clive Svendsen, Dhruv Sareen
  • Publication number: 20200370023
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: July 2, 2020
    Publication date: November 26, 2020
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Patent number: 10745671
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 18, 2020
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20200253684
    Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.
    Type: Application
    Filed: November 15, 2019
    Publication date: August 13, 2020
    Applicant: Cedars-Sinai Medical Center
    Inventors: Pablo Avalos, Doniel Drazin, Clive Svendsen